Episode description
Episode description
Q1 is in the books, and stocks are heading into Q2 with some major accomplishments. Can the market rally keep raging? And where you should be positioned going into the second quarter. Plus… what it really costs to craft these diabetes drugs. A new study pointing to a $5 price tag for a month’s worth of one blockbuster GLP-1 drug. The dollar dichotemy… and if prices will come down for the public.